IRIS
VOSO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 68.029
EU - Europa 3.514
AS - Asia 1.712
Continente sconosciuto - Info sul continente non disponibili 25
SA - Sud America 23
OC - Oceania 22
AF - Africa 13
Totale 73.338
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 67.998
IE - Irlanda 768
IT - Italia 725
CN - Cina 690
UA - Ucraina 669
KR - Corea 490
DE - Germania 468
SG - Singapore 412
GB - Regno Unito 227
FI - Finlandia 186
RU - Federazione Russa 134
FR - Francia 130
SE - Svezia 69
PL - Polonia 47
IN - India 40
CA - Canada 30
AU - Australia 21
EU - Europa 19
JP - Giappone 19
NL - Olanda 17
BE - Belgio 16
HK - Hong Kong 14
BR - Brasile 10
CZ - Repubblica Ceca 10
ES - Italia 10
IR - Iran 10
VN - Vietnam 8
EG - Egitto 7
AT - Austria 5
CH - Svizzera 5
PE - Perù 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CO - Colombia 4
HU - Ungheria 4
ID - Indonesia 4
RO - Romania 4
AL - Albania 3
AR - Argentina 3
BD - Bangladesh 3
GR - Grecia 3
MK - Macedonia 3
PK - Pakistan 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
IL - Israele 2
KZ - Kazakistan 2
MA - Marocco 2
NO - Norvegia 2
RS - Serbia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TR - Turchia 2
TW - Taiwan 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
SD - Sudan 1
Totale 73.338
Salva come PNG Salva come JPEG
Città #
Houston 22.108
Woodbridge 18.291
Wilmington 16.089
Fairfield 2.307
Ann Arbor 1.484
Ashburn 1.046
Seattle 897
Cambridge 834
Chandler 827
Dublin 705
Jacksonville 588
Dearborn 574
Medford 528
Singapore 343
Rome 290
Beijing 272
Lawrence 253
New York 230
Hangzhou 131
San Diego 116
Menlo Park 102
Moscow 100
Milan 73
Santa Clara 70
London 65
Creede 52
Boardman 51
Center 51
Norwalk 41
Engelhard 40
Seoul 40
Kraków 39
Zhengzhou 32
Nanjing 30
Hefei 29
Mountain View 28
Shanghai 28
Hackensack 26
Helsinki 24
Redwood City 24
Chicago 22
Verona 22
Guangzhou 21
Detroit 18
Kunming 18
Toronto 18
Florence 17
Pune 17
Monte Vista 15
Nuremberg 14
Brussels 13
Nanchang 13
Kilburn 12
Bologna 11
Munich 11
Council Bluffs 10
Indiana 10
Jinan 10
Washington 10
Billings 9
Brno 9
Fuzhou 9
Los Angeles 9
Marseille 8
Redmond 8
Saint Petersburg 8
Bari 7
Frankfurt am Main 7
Hong Kong 7
Lappeenranta 7
Mülheim 7
Tokyo 7
Torre Del Greco 7
Brescia 6
Dong Ket 6
New Bedfont 6
Phoenix 6
San Francisco 6
Changsha 5
Chiswick 5
Falls Church 5
Hebei 5
Hounslow 5
Lima 5
Madrid 5
Padova 5
Shenyang 5
Simi Valley 5
Taiyuan 5
Victoria 5
Wuhan 5
Budapest 4
Chennai 4
La Veta 4
Ladenburg 4
Palo Alto 4
Paris 4
San Jose 4
Siena 4
São Paulo 4
Totale 69.380
Salva come PNG Salva come JPEG
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.338
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.619
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.578
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.225
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.155
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 469
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 469
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 432
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 422
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 419
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 417
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 416
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 416
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 416
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 415
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 411
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 409
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 407
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 403
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 402
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 400
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 398
Panobinostat for the treatment of acute myelogenous leukemia 397
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 395
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 394
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 394
Clonal evolution in therapy-related neoplasms 394
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 393
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 391
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 391
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 390
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 388
Therapy related leukemias: susceptibility, prevention and treatment 387
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 387
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 386
Small lymphocytic lymphoma in a patient with Fabry disease 385
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 385
Mobilization and selection of CD34+ cells 385
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 385
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 383
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 382
New treatments for myelodysplastic syndromes 382
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 382
Prevalence of obesity in young adults with acute lymphoblastic leukemia 381
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 381
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 381
Hepato-splenic mycotic abscesses in patients with acute leukemia 381
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 380
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 380
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 379
Epigenetic changes in therapy-related MDS/AML 378
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 377
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 376
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 376
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 374
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 372
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 372
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 370
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 370
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 369
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 369
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 368
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 368
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 368
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 367
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 367
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 366
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 366
Why methylation is not a marker predictive of response to hypomethylating agents 366
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 365
Incidence and susceptibility to therapy-related myeloid neoplasms 364
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 364
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 363
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 363
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 363
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 362
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 362
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 361
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 361
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 360
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 359
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 356
Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker 355
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 354
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 354
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 354
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 354
Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan 352
Fanconi anemia gene variants in therapy-related myeloid neoplasms 352
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 352
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 351
Outcome of therapy-related myeloid neoplasms treated with azacitidine 351
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 350
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 350
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms 349
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 349
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 349
Inhibition of hematopoiesis by competitive binding of transcription factor PU.1 349
Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms 345
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 345
Totale 43.912
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.842
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017.132 0 1.327 1.222 1.891 1.671 2.018 1.801 1.779 1.832 1.422 1.096 1.073
2020/202110.816 1.263 1.138 1.160 1.230 1.378 1.094 1.365 1.083 285 266 447 107
2021/20222.502 118 293 127 61 78 209 129 149 178 144 268 748
2022/20232.777 340 176 135 272 182 699 486 120 208 20 77 62
2023/20241.303 127 38 149 56 125 347 67 33 51 40 30 240
2024/2025697 179 518 0 0 0 0 0 0 0 0 0 0
Totale 74.520